WHO Sounds Warning Over Acute Lack of Weight-Loss Jabs
Fewer than a tenth of individuals that would benefit from obesity jabs including Wegovy are able to get them, caution the World Health Organization as it issues its inaugural guidance on the therapies.
Considering over a billion people worldwide currently obese, it is urging more widespread and fairer access to these injectable treatments.
Based on estimates, more than two billion are projected to be living with obesity by 2030 if no action is taken.
"Our latest guidance recognises that excess weight is a lifelong illness that can be addressed with comprehensive and continuous care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are key obstacles to universal availability to the treatments that can aid individuals in losing significant weight, says the agency.
GLP-1 Therapy Shortage
Despite the present most optimistic case, the supply of such drugs would only suffice for around 100 million people – under 10% of those who need them, according to the health organization.
The recommendation urges nations and manufacturers to increase availability, through strategies like voluntary licensing.
The intellectual property rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026.
How Obesity Injections Operate
The injections mimick a biological compound to slow digestion, suppress the appetite and increase the sense of being full so users eat less.
Patients typically start to lose weight after several weeks of commencing the weekly injections.
Evidence indicates users may regain a significant portion within a year of halting the medication, when their normal hunger return.
To be above a healthy weight increases your chance for developing medical conditions, such as type 2 diabetes, heart disease, brain attack, and some malignancies.
Excess weight concerns people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, as per the health agency.
